Demographics and clinical characteristics of patients with MM at diagnosis included in study (N = 11 427)
| . | ALC, ×103/μL . | P value . | |||
|---|---|---|---|---|---|
| Overall . | Severely low . | Low . | Normal . | ||
| Number of patients, n (%)∗ | 11 427 | 2796 (24) | 3292 (29) | 5339 (47) | |
| Age at diagnosis, median (IQR), y | 69.8 (63.0-76.8) | 71.2 (64.7-77.7) | 70.6 (64.2-77.2) | 68.4 (61.5-75.9) | <.001 |
| Median follow-up, median (IQR) | 2.3 (0.9-4.5) | 1.9 (0.7-3.9) | 2.2 (0.9-4.4) | 2.6 (1.1-4.9) | <.001 |
| Age ≥65 y at diagnosis | 7 782 | 2074 (26.7) | 2359 (30.3) | 3349 (43.0) | <.001 |
| Male sex, n (%) | 11 142 | 2745 (24.6) | 3234 (29.0) | 5163 (46.3) | <.001 |
| Race, n (%) | <.001 | ||||
| Black | 2 942 | 558 (19.0) | 788 (26.8) | 1596 (54.2) | |
| White | 6 880 | 1786 (26.0) | 2045 (29.7) | 3049 (44.3) | |
| Other | 157 | 39 (24.8) | 40 (25.5) | 78 (49.7) | |
| Ethnicity, n (%) | <.001 | ||||
| Hispanic or Latino | 561 | 121 (21.6) | 148 (26.4) | 292 (52.0) | |
| Not Hispanic or Latino | 9 712 | 2331 (24.0) | 2817 (29.0) | 4564 (47.0) | |
| Smoking status (%) | <.001 | ||||
| Never | 2 224 | 594 (26.7) | 676 (30.4) | 954 (42.9) | |
| Current/former | 8 402 | 1947 (23.2) | 2376 (28.3) | 4079 (48.5) | |
| CCI score† | <.001 | ||||
| No comorbidities or mild (1-2) | 6 417 (56.2) | 1510 (54.0) | 1837 (55.8) | 3070 (57.5) | |
| Moderate (3-4) | 3 327 (29.1) | 823 (29.4) | 950 (28.9) | 1554 (29.1) | |
| Severe (>5) | 1 187 (10.4) | 328 (11.7) | 350 (10.6) | 509 (9.5) | |
| Distribution of ISS stages across the 3 ALC groups, n (%)† | <.001 | ||||
| Stage I | 1 369 (12.0) | 257 (9.2) | 390 (11.8) | 722 (13.5) | |
| Stage II | 2 362 (20.7) | 517 (18.5) | 655 (19.9) | 1190 (22.3) | |
| Stage III | 2 308 (20.2) | 569 (20.4) | 658 (20.0) | 1081 (20.2) | |
| β2m | <.001 | ||||
| β2m >3.5 μg/mL (%) | 3 838 | 875 (22.8) | 1102 (28.7) | 1861 (48.5) | |
| Serum albumin† | <.001 | ||||
| Albumin <3.5 g/dL (%) | 5 228 (45.8) | 1410 (50.4) | 1452 (44.1) | 2366 (44.3) | |
| Albumin, median (IQR), g/dL | 3.5 (3.0-3.9) | 3.4 (2.9, 3.8) | 3.5 (3.0-3.9) | 3.5 (3.0-3.9) | |
| Creatinine, median (IQR), mg/dL | 1.2 (1.0-1.8) | 1.2 (1.0-1.9) | 1.3 (1.0-1.8) | 1.2 (1.0-1.7) | .309 |
| Serum LDH | <.001 | ||||
| LDH >243 U/L, n (%) | 1 221 | 325 (26.6) | 339 (27.8) | 557 (45.6) | |
| MM diagnosis date, n (%) | .023 | ||||
| <2007 | 2 727 | 724 (26.5) | 794 (29.1) | 1209 (44.3) | |
| ≥2007 to <2012 | 2 702 | 652 (24.1) | 782 (28.9) | 1268 (46.9) | |
| ≥2012 | 5 998 | 1420 (23.7) | 1716 (28.6) | 2862 (47.7) | |
| . | ALC, ×103/μL . | P value . | |||
|---|---|---|---|---|---|
| Overall . | Severely low . | Low . | Normal . | ||
| Number of patients, n (%)∗ | 11 427 | 2796 (24) | 3292 (29) | 5339 (47) | |
| Age at diagnosis, median (IQR), y | 69.8 (63.0-76.8) | 71.2 (64.7-77.7) | 70.6 (64.2-77.2) | 68.4 (61.5-75.9) | <.001 |
| Median follow-up, median (IQR) | 2.3 (0.9-4.5) | 1.9 (0.7-3.9) | 2.2 (0.9-4.4) | 2.6 (1.1-4.9) | <.001 |
| Age ≥65 y at diagnosis | 7 782 | 2074 (26.7) | 2359 (30.3) | 3349 (43.0) | <.001 |
| Male sex, n (%) | 11 142 | 2745 (24.6) | 3234 (29.0) | 5163 (46.3) | <.001 |
| Race, n (%) | <.001 | ||||
| Black | 2 942 | 558 (19.0) | 788 (26.8) | 1596 (54.2) | |
| White | 6 880 | 1786 (26.0) | 2045 (29.7) | 3049 (44.3) | |
| Other | 157 | 39 (24.8) | 40 (25.5) | 78 (49.7) | |
| Ethnicity, n (%) | <.001 | ||||
| Hispanic or Latino | 561 | 121 (21.6) | 148 (26.4) | 292 (52.0) | |
| Not Hispanic or Latino | 9 712 | 2331 (24.0) | 2817 (29.0) | 4564 (47.0) | |
| Smoking status (%) | <.001 | ||||
| Never | 2 224 | 594 (26.7) | 676 (30.4) | 954 (42.9) | |
| Current/former | 8 402 | 1947 (23.2) | 2376 (28.3) | 4079 (48.5) | |
| CCI score† | <.001 | ||||
| No comorbidities or mild (1-2) | 6 417 (56.2) | 1510 (54.0) | 1837 (55.8) | 3070 (57.5) | |
| Moderate (3-4) | 3 327 (29.1) | 823 (29.4) | 950 (28.9) | 1554 (29.1) | |
| Severe (>5) | 1 187 (10.4) | 328 (11.7) | 350 (10.6) | 509 (9.5) | |
| Distribution of ISS stages across the 3 ALC groups, n (%)† | <.001 | ||||
| Stage I | 1 369 (12.0) | 257 (9.2) | 390 (11.8) | 722 (13.5) | |
| Stage II | 2 362 (20.7) | 517 (18.5) | 655 (19.9) | 1190 (22.3) | |
| Stage III | 2 308 (20.2) | 569 (20.4) | 658 (20.0) | 1081 (20.2) | |
| β2m | <.001 | ||||
| β2m >3.5 μg/mL (%) | 3 838 | 875 (22.8) | 1102 (28.7) | 1861 (48.5) | |
| Serum albumin† | <.001 | ||||
| Albumin <3.5 g/dL (%) | 5 228 (45.8) | 1410 (50.4) | 1452 (44.1) | 2366 (44.3) | |
| Albumin, median (IQR), g/dL | 3.5 (3.0-3.9) | 3.4 (2.9, 3.8) | 3.5 (3.0-3.9) | 3.5 (3.0-3.9) | |
| Creatinine, median (IQR), mg/dL | 1.2 (1.0-1.8) | 1.2 (1.0-1.9) | 1.3 (1.0-1.8) | 1.2 (1.0-1.7) | .309 |
| Serum LDH | <.001 | ||||
| LDH >243 U/L, n (%) | 1 221 | 325 (26.6) | 339 (27.8) | 557 (45.6) | |
| MM diagnosis date, n (%) | .023 | ||||
| <2007 | 2 727 | 724 (26.5) | 794 (29.1) | 1209 (44.3) | |
| ≥2007 to <2012 | 2 702 | 652 (24.1) | 782 (28.9) | 1268 (46.9) | |
| ≥2012 | 5 998 | 1420 (23.7) | 1716 (28.6) | 2862 (47.7) | |
IQR, interquartile range.
Data available for 9979 patients (87.3%) on race, 10 273 patients (90%) on ethnicity, 10 626 patients (93%) on smoking status, 10 931 patients (96%) on CCI score, 6039 patients (53%) on stage, 6079 patients (53%) on β2m, and 6146 patients (54%) on LDH.
Denotes column percentages.